A report of worse sleep after DSIP should not automatically be answered with a new timing schedule or a larger amount. The observation does not establish why sleep changed, and the available evidence does not provide a validated adjustment rule for a research product.
Do not turn an adverse experience into proof of benefit
Online replies sometimes describe initial sleep disruption as a necessary adjustment or evidence that a peptide is influencing sleep architecture. That explanation requires evidence. Repeating it can encourage further exposure without addressing the symptom.
The FDA's emideltide review found limited and inconsistent clinical evidence, with insufficient characterization of safety for the proposed subcutaneous use. It does not establish that worsening insomnia is a predictable stage on the way to improvement.
Record the sequence without assuming the cause
A useful account includes when the sleep change began, what was used, other medicines or substances, and whether the problem involves falling asleep, waking repeatedly or waking too early. Keep product packaging and available records.
The same timeline can support several explanations. A coincident illness, a change in schedule, another medicine or the material itself may need consideration. A clinician can evaluate these possibilities; a brief forum exchange cannot resolve them.
The NHLBI's diagnostic guidance describes how a sleep diary can help make the pattern clearer. That record is information for assessment, not an experiment requiring continued exposure.
Reassess rather than escalate
If symptoms are new, persistent or affecting daytime safety, obtain medical advice. Avoid driving or hazardous work when dangerously sleepy. If something was prescribed, contact the prescriber or pharmacist rather than independently replacing or changing the treatment.
This article cannot establish that DSIP caused a particular person's insomnia. It also cannot assure them that another attempt would be safe or more effective.
The practical answer to nonresponse is not an automatic protocol adjustment. It is to revisit the diagnosis, product identity, expected benefit and risks with a qualified professional.